A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer

Documenti analoghi

• Dynamic T‐Cell Reprogramming Modulates the Treatment Outcome of Neoadjuvant Immunochemotherapy in Non‐Small‐Cell Lung Cancer
  di: Rui Jin, et al.
  Pubblicazione: (2026)
• Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study
  di: Jiayi Wang, et al.
  Pubblicazione: (2026)
• Radiotherapy after Neoadjuvant Immunochemotherapy in Unresectable Stage III Non‐Small Cell Lung Carcinoma: A Novel Therapeutic Approach?
  di: Peizhu Wu, et al.
  Pubblicazione: (2025)
• Real‐World Outcomes of Induction Immunochemotherapy Followed by Surgery for Advanced Non‐Small Cell Lung Cancer
  di: Xingqi Mi, et al.
  Pubblicazione: (2026)
• Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non‐Small Cell Lung Cancer
  di: Jianyi Yang, et al.
  Pubblicazione: (2026)